861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells

861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells

Bibliographic Details
Main Authors: Andrew Rankin, Edwina Naik
Format: Article
Language:English
Published: BMJ Publishing Group 2020-11-01
Series:Journal for ImmunoTherapy of Cancer
id doaj-441b7f37a97d4d468d6aa2d5bd6dbe38
record_format Article
spelling doaj-441b7f37a97d4d468d6aa2d5bd6dbe382020-12-11T10:04:29ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-11-018Suppl 310.1136/jitc-2020-SITC2020.0861861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cellsAndrew Rankin0Edwina Naik1Five Prime Therapeutics, South San Francisco, CA, USAFive Prime Therapeutics, South San Francisco, CA, USA
collection DOAJ
language English
format Article
sources DOAJ
author Andrew Rankin
Edwina Naik
spellingShingle Andrew Rankin
Edwina Naik
861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
Journal for ImmunoTherapy of Cancer
author_facet Andrew Rankin
Edwina Naik
author_sort Andrew Rankin
title 861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
title_short 861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
title_full 861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
title_fullStr 861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
title_full_unstemmed 861 Development of FPA157, an anti-CCR8 depleting antibody engineered to preferentially eliminate tumor-infiltrating T regulatory cells
title_sort 861 development of fpa157, an anti-ccr8 depleting antibody engineered to preferentially eliminate tumor-infiltrating t regulatory cells
publisher BMJ Publishing Group
series Journal for ImmunoTherapy of Cancer
issn 2051-1426
publishDate 2020-11-01
work_keys_str_mv AT andrewrankin 861developmentoffpa157ananticcr8depletingantibodyengineeredtopreferentiallyeliminatetumorinfiltratingtregulatorycells
AT edwinanaik 861developmentoffpa157ananticcr8depletingantibodyengineeredtopreferentiallyeliminatetumorinfiltratingtregulatorycells
_version_ 1724386442623320064

Similar Items